Back to Gastroenterology
Gastroenterologyv2006Evidence-Based

Fibrosis-4 (FIB-4) Index for Liver Fibrosis

Non-invasive estimate of liver scarring in HCV and HBV patients, to assess need for biopsy. Calculated as (Age × AST) / (Platelet count × √ALT)

Clinical Input Parameters

years
Range: 18 — 120 years
U/L
Range: 1 — 10000 U/L
U/L
Range: 1 — 10000 U/L
10⁹/L
Range: 1 — 1000 10⁹/L
Clinical Assessment
Awaiting Parameters
fib4 score
—index
Ready to Calculate

Awaiting Clinical Input

Enter the clinical input parameters on the left and click Run Clinical Assessment to evaluate this medical calculator with deterministic clinical scoring.

Open in Web App
Clinical decision support tool for licensed medical practitioners. Confirm independently before prescribing or clinical action.

When & Why to Use

The Fibrosis-4 (FIB-4) Index for Liver Fibrosis is utilized in clinical practice for risk stratification, diagnostic probability estimation, and treatment decision-making within gastroenterology.

Use this tool during initial patient intake, emergency department workup, or bedside assessment when objective clinical scoring is required to guide management or admission decisions.

Clinical Formula & Scoring Logic

FIB-4 = (Age × AST) / (Platelet count × √ALT)

Clinical Pearls & Practice Notes

  • Use with caution in patients <35 or >65 years old
  • For patients >65 years, consider using a cutoff of 2.0 instead of 1.45
  • Originally developed for HIV/HCV coinfection but validated in NAFLD, HBV, and HCV
  • Platelet count should be in 10⁹/L (not 10³/µL) for this calculation

Evidence & Literature Citations

  1. Sterling RK, Lissen E, Clumeck N, Sola R, Correa MC, Montaner J, et al. Development of a simple noninvasive index to predict significant fibrosis in patients with HIV/HCV coinfection. Hepatology. 2006 Jun;43(6):1317-25. doi: 10.1002/hep.21178.
  2. Vallet-Pichard A, Mallet V, Nalpas B, Verkarre V, Nalpas A, Dhalluin-Venier V, et al. FIB-4: an inexpensive and accurate marker of fibrosis in HCV infection. comparison with liver biopsy and fibrotest. Hepatology. 2007 Jul;46(1):32-6. doi: 10.1002/hep.21669.
  3. Shah AG, Lydecker A, Murray K, Tetri BN, Contos MJ, Sanyal AJ, et al. Comparison of noninvasive markers of fibrosis in patients with nonalcoholic fatty liver disease. Clin Gastroenterol Hepatol. 2009 Oct;7(10):1104-12. doi: 10.1016/j.cgh.2009.05.033.

Score Interpretation Ranges

Low risk0 – 1.45 pts

Low risk of advanced fibrosis (F0-F1)

Indeterminate risk1.45 – 3.25 pts

Indeterminate risk (F2-F3)

High risk3.25 – 999999 pts

High risk of advanced fibrosis/cirrhosis (F3-F4)

Need Clinical Suite Access?

Run this calculator with patient history, laboratory integration, and drug interaction safety checks on the DexaMed clinician app.

Open in Web App

Clinical Decision Support (CDS) Notice & Legal Disclaimer

This medical calculator and its scoring interpretation are provided strictly for licensed healthcare professionals and medical trainees as an educational and clinical decision support instrument. It does not replace independent clinical judgment, comprehensive patient history, physical examination, or attending physician oversight. Not FDA-cleared as an autonomous diagnostic medical device. Read the full DexaMed Medical Disclaimer.